Claris Lifesciences plans to expand capacity at new plant

Claris Lifesciences is reportedly planning to expand the capacity of its newly commissioned facility, Plant 2, for which it received approval from UK’s MHRA recently. “The company has plans to install another line in this new plant (Plant 2) which will be ready for commercial production by the end of this year. The existing line has capabilities to manufacture aseptic sterilised products as well, and the new line will have the capacity to manufacture lyophilised products,” said Claris Lifesciences in a press release.
 
On August 20, 2014, Claris Lifesciences announced that it has received approval from UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) for terminally sterilised products presented in glass ampoules manufactured in line 1 of the Plant 2. Claris' flagship facility (ie, Plant 1) is already approved by MHRA-UK.
 
The latest MHRA approval is expected to help the company to enhance capacities to grow in the regulated markets, especially the European region. The company's specialty injectables business saw a growth of 30% in the last quarter.
 
Claris Lifesciences, which is currently functioning at high capacity utilisation, set up the Plant 2 to increase capacities to service future demands. "To sustainably grow, attaining the required regulatory approvals is one of the key growth drivers, and the company has a large pipeline of products, which includes the under approval and the products currently under development,” the company said in the release.